# Viz.ai

> Viz.ai is an AI-powered care coordination platform trusted by over 2,000 hospitals across the United States. The company's suite of 50+ FDA-cleared algorithms analyzes medical imaging data in real time - detecting strokes, brain hemorrhages, aneurysms, pulmonary embolisms, and cardiac conditions - then instantly alerts the right clinical team so treatment can begin minutes faster. Founded in 2016 by neurosurgeon Dr. Chris Mansi and machine learning researcher Dr. David Golan, Viz.ai has grown into a platform covering 230 million lives, supporting 70,000+ healthcare providers, and partnering with 14+ leading pharmaceutical companies to accelerate drug development and patient access.

- **Founded:** 2016
- **Headquarters:** San Francisco, California, United States
- **Founders:** Dr. Chris Mansi (CEO & Co-founder), Dr. David Golan (Co-founder), Manoj Ramachandran (Co-founder)
- **Team size:** ~320 employees across 5 continents
- **Products:** Viz One, Viz Neuro Suite, Viz Cardio Suite, Viz Vascular Suite, Viz Trauma Suite
- **Notable:** First company to receive CMS reimbursement for AI, First-ever FDA De Novo approval for AI computer-aided triage and notification for LVO stroke (February 2018), Second De Novo FDA approval for Viz HCM cardiovascular ML module (August 2023)

## Products & services

- **Viz One** — The core AI-powered intelligent care coordination platform - unifies detection, triage, communication, and patient activation across specialties.
- **Viz Neuro Suite** — AI algorithms for neurovascular disease detection including large vessel occlusion (LVO) stroke, intracranial hemorrhage, subdural hemorrhage, and cerebral aneurysm.
- **Viz Cardio Suite** — Cardiovascular AI including Viz HCM for hypertrophic cardiomyopathy detection and management - the first De Novo FDA-cleared cardiovascular ML notification software.
- **Viz Vascular Suite** — AI-powered workflow tools for vascular medicine including abdominal aortic aneurysm detection.
- **Viz Trauma Suite** — AI tools for trauma care coordination and triage.
- **Viz Radiology Suite** — Diagnostic acceleration tools for radiology departments.
- **Viz Pulmonary Suite** — Comprehensive pulmonary care delivery including Viz PE for pulmonary embolism detection with automated RV/LV ratio analysis.
- **Viz Oncology Suite** — AI-powered workflows for oncology care, developed in partnership with Novartis.
- **Viz Hub** — HIPAA-compliant clinical messaging and care team collaboration tool.
- **Viz View** — Mobile PACS viewer for imaging review on any device.
- **Viz Assist** — Workflow assistant for clinical and administrative tasks, with Salesforce and Microsoft integrations.
- **Viz Agent Studio** — Launched March 2026 - first agentic platform enabling health systems to create their own AI Care Pathways using natural language. Translates clinical guidelines into executable workflows.
- **Life Sciences Platform** — AI-powered care accelerator for pharmaceutical and medical device companies - surfaces treatment-eligible patients and measures real-world drug impact.

## Achievements

- First company to receive CMS reimbursement for AI
- First-ever FDA De Novo approval for AI computer-aided triage and notification for LVO stroke (February 2018)
- Second De Novo FDA approval for Viz HCM cardiovascular ML module (August 2023)
- 50+ FDA-cleared AI-powered solutions
- Three consecutive Edison Awards for machine learning innovation (2023, 2024, 2025)
- Ranked #1 Healthcare AI Platform by Black Book Research for two consecutive years
- Named to TIME Magazine World's Top Health Companies 2025
- CEO Chris Mansi recognized by Goldman Sachs as one of the Most Exceptional Entrepreneurs of 2023
- 120+ clinical publications and abstracts supporting the platform
- Achieved profitability in healthcare business in 2025
- 11-minute reduction in door-to-groin time for stroke treatment
- 92.3% accuracy in intracranial hemorrhage detection

## Latest updates

- **2026-03** — Launched Viz Agent Studio - first agentic AI platform enabling health systems to build custom AI Care Pathways using plain-language instructions.
- **2026-03** — Partnered with Alnylam Pharmaceuticals to advance early identification of cardiac amyloidosis patients.
- **2026-01** — Announced partnership with Salesforce to integrate real-time clinical data into Agentforce Life Sciences.
- **2026-01** — Closed 2025 with record scale: 2,000 hospitals, 70,000+ providers, achieved profitability in healthcare business, doubled life sciences in 18 months.
- **2025-05** — Partnered with Regeneron and Sanofi to study AI-enabled COPD workflow tool.
- **2025-04** — Won third consecutive Edison Award for machine learning innovation (Viz HCM module).
- **2025** — Launched Viz Oncology Suite (with Novartis) and Viz Pulmonary Suite.
- **2025** — Named to TIME Magazine World's Top Health Companies 2025.
- **2024-02** — Received FDA 510(k) clearance for Viz ICH Plus - intracranial hemorrhage identification and quantification.

## Links

- Website: https://viz.ai
- LinkedIn: https://www.linkedin.com/company/viz-ai
- Twitter/X: https://twitter.com/viz_ai
- Facebook: https://www.facebook.com/viz.ai.hq

---

Profile page: https://yespress.io/viz-ai
Published by YesPress — https://yespress.io
Last updated: 2026-05-18